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Abstract
Background
Several studies have reported an increased risk of wheezing in the children of mothers who
used paracetamol during pregnancy. We evaluated to what extent this association is
explained by confounding.
Methods
We investigated the association between maternal paracetamol use in the first and third tri-
mester of pregnancy and ever wheezing or recurrent wheezing/asthma in infants in the NIN-
FEA cohort study. Risks ratios (RR) and 95% confidence intervals (CI) were estimated after
adjustment for confounders, including maternal infections and antibiotic use during
pregnancy.
Results
The prevalence of maternal paracetamol use was 30.6% during the first and 36.7% during
the third trimester of pregnancy. The prevalence of ever wheezing and recurrent wheezing/
asthma was 16.9% and 5.6%, respectively. After full adjustment, the RR for ever wheezing
decreased from 1.25 [1.07–1.47] to 1.10 [0.94–1.30] in the first, and from 1.26 [1.08–1.47]
to 1.10 [0.93–1.29] in the third trimester. A similar pattern was observed for recurrent
wheezing/asthma. Duration of maternal paracetamol use was not associated with either
outcome. Further analyses on paracetamol use for three non-infectious disorders (sciatica,
migraine, and headache) revealed no increased risk of wheezing in children.
Conclusion
The association between maternal paracetamol use during pregnancy and infant wheezing
is mainly, if not completely explained by confounding.
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Introduction
Paracetamol is one of the most commonly used medications in pregnant women and has
almost completely replaced aspirin as an analgesic and antipyretic in children. In late 1980s,
some authors suggested that this increase in paracetamol use might contribute to an increase in
the prevalence of asthma, particularly in the paediatric population [1].
An association between paracetamol exposure in early childhood and the occurrence of
asthma in school-age children has been reported and reviewed repeatedly [2–4]. However, the
observational and frequently retrospective design of the majority of these studies did not allow
firm conclusions to be drawn regarding the causality of the observed association. The most
recent evidence [2, 3, 5] suggests that the association between paracetamol exposure in early
childhood and paediatric asthma may be at least partly due to different types of bias, particu-
larly confounding by indication. Indeed, paracetamol is used to treat several disorders in chil-
dren, the most important being respiratory tract infections, which are also associated with
wheezing and asthma development [6]. In fact, Cheelo et al. [3] observed that the association
between paracetamol exposure in early childhood and subsequent paediatric asthma decreased
when the data were also adjusted for early respiratory tract infections. This finding was con-
firmed in the recent study by Sordillo et al. [5]. Furthermore, there were two studies in the
review by Cheelo et al. [3] that examined the effects of paracetamol given to children for non-
respiratory infections [6, 7], and neither found an increased risk of asthma associated with
paracetamol use.
Some cohort studies have reported an association between maternal paracetamol use during
pregnancy and risk of wheezing or asthma in children [3, 5, 8, 9]. However, as this evidence is
also based on observational studies it is still unclear whether the association between maternal
paracetamol use in pregnancy and wheezing or asthma in children is causal or at least partly
spurious [3, 4, 8]. Maternal paracetamol use could be a proxy for maternal disorders that are
associated with childhood asthma, such as respiratory infections [10]. Furthermore, wheezing
in childhood, particularly in early childhood, is often triggered by infections. Therefore, in
addition to the infections themselves, any condition that favours or is associated with maternal
infections (e.g. maternal smoking, maternal antibiotic use, siblings) could be related to an
increased risk of infection in children and thus to wheezing in children who are predisposed. It
should also be noted that the association between paracetamol use during pregnancy and
asthma in school-aged children has not been supported in some studies [5, 11–14].
We used data from the NINFEA (Nascita e INFanzia: gli Effetti dell'Ambiente) cohort
study, an Italian birth cohort study, to assess to what extent the potential association between
maternal paracetamol use and ever or recurrent infant wheezing/asthma is explained by
confounding.
Materials and Methods
The NINFEA cohort study is an ongoing web-based birth cohort. It was started in 2005 in the
city of Turin and was progressively extended to the rest of Italy, with the aim of investigating
the effects of early-life exposures on the health of newborns, adolescents, and adults (www.
progettoninfea.it) [15]. Cohort members are children of mothers who have access to the inter-
net and have enough knowledge of the Italian language to complete online questionnaires. The
existence of the study is actively publicised in hospitals and obstetrical clinics, with the collabo-
ration of health personnel who distribute leaflets and posters; it is also passively publicised on
the internet via links and discussion forums. Approximately 75% of participants are recruited
through active methods, 20% through passive methods, and 5% through both methods.
Women who are interested in participating in the study complete a first online questionnaire
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(baseline questionnaire) at any time during their pregnancy. This is followed by four follow-up
online questionnaires, which are completed by the mothers when their child turns 6 months,
18 months, 4 years, and 7 years of age, respectively. Members of the NINFEA cohort study
originate from a selected population, but baseline selection does not imply biased associational
estimates in cohort studies [16–18]. The NINFEA cohort study was approved by the Ethical
Committee of the San Giovanni Battista Hospital-CTO/CRF/Maria Adelaide Hospital of
Turin. Online written informed consent was obtained from all the mothers of the study partici-
pants at the time of completing the first questionnaire, in accordance with IRB approval.
Data were obtained from the NINFEA database version 2013.03. Children with available
information on the outcome and exposure of interest, and whose mothers had filled in both
baseline questionnaire, and the 6-month and the 18-month questionnaire (response propor-
tion for 18-month questionnaire: 84%) at the time of data download were eligible for inclusion.
Children born to mothers who had filled in the baseline questionnaire before the end of their
first trimester of pregnancy were excluded due to incomplete information on the first
trimester.
Exposure data
Information on maternal paracetamol use and duration of paracetamol use (number of days)
was obtained from the baseline questionnaire for the first trimester of pregnancy and from the
6-month questionnaire for the third trimester of pregnancy (S1 Table).
We also evaluated maternal paracetamol use during pregnancy for three non-infectious
disorders that are frequently treated with paracetamol: sciatica, headache, and migraine (S2
Table). These disorders are included in a pre-defined checklist of diseases in the baseline ques-
tionnaire; women were asked to report if they had ever been diagnosed with these disorders
by a doctor, and if so the drugs they used to treat them in the first and third trimester of
pregnancy.
We did not consider maternal paracetamol use in the second trimester of pregnancy due to
a lack of information. Indeed, as women could complete the baseline questionnaire at any time
during their pregnancy, those who completed the baseline questionnaire before their 6th
month of pregnancy had complete information on the first trimester but not on the second
trimester.
Information on duration of paracetamol use was collected in the questionnaire using pre-
specified categories (1–2 days, 3–7 days and more than 7 days per month) until 2008. Thereaf-
ter, information was collected using the actual number of days. We harmonised the two ver-
sions of the questionnaire by converting the categorical variable into the corresponding
stratum-specific average number of days.
Outcome variables
Information on the outcomes ever wheezing and recurrent wheezing/asthma was obtained
from the 6-month and 18-month questionnaires, which used questions derived from the
ISAAC questionnaires (S3 Table) [19]. Ever wheezing was defined as at least one episode of
wheezing or whistling in the chest in the first 6 months of life, or between 6 and 18 months of
life. Recurrent wheezing/asthma was defined as wheezing reported in both the 6-month and
18-month questionnaires or asthma diagnosed by a doctor in either of these questionnaires.
Statistical analyses
Crude risks ratios (RRcrude) and adjusted RR (RRadjusted) were estimated using poisson regres-
sion models, separately for maternal paracetamol use in the first and third trimester of
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pregnancy. Models were first adjusted for several maternal characteristics, conditions, and
disorders that are potentially associated with infant wheezing and possibly associated with
paracetamol use during pregnancy (educational level, age at delivery, smoking during preg-
nancy, siblings, asthma/asthmatic bronchitis, and maternal allergic rhinitis/hay fever) [3, 20].
Models were then further adjusted for maternal respiratory tract infections in the first or
third trimester of pregnancy (otitis/sinusitis/ throat infection, bronchitis or flu, and cold) and
for factors associated with maternal infections (fever>38°C and antibiotic use during preg-
nancy) [2, 3]. The rationale for this additional adjustment was that maternal infection may be
associated with the risk of respiratory diseases in children and may also indicate maternal
paracetamol use.
We also modelled paracetamol use for the three non-infectious maternal disorders (sciatica,
headache, and migraine) separately in the first and third trimester of pregnancy in association
with ever wheezing and recurrent wheezing/asthma. Specifically, we compared mothers who
used paracetamol to treat any of these disorders with mothers affected by these disorders who
did not use paracetamol to treat their symptoms. These non-infectious disorders were selected
because they are not risk factors for wheezing or asthma; as such they can be used to discrimi-
nate between mothers who did and did not use paracetamol for disorders that are unrelated to
the risk of wheezing or asthma in children, by assuming paracetamol use for other diseases is
equally distributed in each category. This analysis was adjusted only for the first set of
confounders.
Since women could contribute more than one pregnancy to the cohort, we estimated robust
variance using clustered sandwich estimators to allow for intra-group correlation. All regres-
sion models were performed on the set of children with no missing data for any of the outcome,
exposure, or confounding variables.
The relationship between wheezing and duration of the paracetamol use (expressed as incre-
ment of risk per day of use) in the first and third trimester was further studied by a restricted
cubic spline regression of days of use to test whether there was a non-linear dose-response
shape. In a sensitivity analysis, we evaluated the robustness of our results using a propensity
score-based analysis.[21] Specifically, the probability of paracetamol use was modelled condi-
tioning on potential determinants of paracetamol use, such as maternal allergic rhinitis, asthma
and asthmatic bronchitis, maternal disorders in the first/third trimester of pregnancy which
may or not may be treated with paracetamol, and maternal antibiotic use. After checking for
the absence of subjects outside the region of common support of the propensity score, the
score was introduced in the poisson regression model for the outcome variables, further adjust-
ing for maternal age at delivery, the maternal characteristics educational level, age at delivery,
smoking during pregnancy, and parity.
All analyses concerning the third trimester were further adjusted for gestational duration,
as, keeping all other things the same, the probability of taking any drug is, by definition, higher
in a longer than a shorter pregnancy. Analyses were performed using statistical software
STATA 12.1.
Results
There were 4254 children born to mothers who filled in the 18-month questionnaire. We
excluded 144 because they were twins, and 572 because the baseline questionnaire was com-
pleted before the end of the first trimester of pregnancy. Of the remaining 3538 children, 94.9%
(n = 3358) had information both on the outcomes of interest and paracetamol exposure in the
first trimester, and 3251 (91.9%) had information both on the outcomes of interest and para-
cetamol exposure in the third trimester.
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Prevalence of maternal paracetamol use was 30.6% (1026 children exposed) during the first
trimester and 36.7% (1194 children exposed) during the third trimester of pregnancy. The
mean duration of paracetamol use was 3.3 days (standard deviation, SD 3.84 days/trimester)
and 3.7 days (SD 4.55 days/trimester) in the first and third trimester respectively. The percent-
age of mothers reporting 5 or more days of paracetamol use was 5.5% and 6.4% in the first and
third trimester respectively.
Maternal socio-demographic characteristics and potential confounders in users and non-
users of paracetamol are presented in Table 1. Maternal smoking during pregnancy, presence
of siblings, and maternal antibiotic use during pregnancy were more frequent among users of
paracetamol than among non-users. Similarly, maternal asthma or allergies, maternal respira-
tory diseases and in general all maternal disorders both in the first and in the third trimester of
pregnancy, were more frequent among paracetamol users than non-users (Table 1). The overall
prevalence of ever wheezing in the first 18 months of life was 16.9% (567 out of 3358) and the
prevalence of recurrent wheezing/asthma was 5.6% (189 out of 3358).
All regression models were performed on 3268 children with complete data (i.e., no missing
data for any of the outcomes, exposures, or confounding variables) for analyses on the first tri-
mester and on 3180 children for analyses on the third trimester of pregnancy.
In the crude analysis, compared to unexposed infants, the risk of ever wheezing was higher
in infants exposed to paracetamol in both the first and third trimester of pregnancy (Table 2).
Adjustment for the first set of potential confounders reduced the relative risks by about 9% for
infants exposed in the first trimester and by 13% for those exposed in the third trimester. The
relative risks further decreased after adjusting for maternal infections during pregnancy (by
about 6% for exposure in the first trimester and 4% for exposure in the third trimester). A simi-
lar pattern was observed for recurrent wheezing/asthma, although analyses were based on a
smaller number of events (Table 2).
In adjusted analyses, duration of paracetamol use during the first trimester as well as the
third trimester of pregnancy was not associated with an increased risk of recurrent wheezing/
asthma in the first 18 months of life (first trimester: RRadjusted = 0.99 [95% CI 0.95–1.02] for
ever wheezing and RRadjusted = 0.96 [95% CI 0.89–1.03] for recurrent wheezing/asthma; third
trimester: RRadjusted = 1.00 [95% CI 0.98–1.02] for ever wheezing, RRadjusted = 0.99 [95% CI
0.94–1.04] for recurrent wheezing/asthma; data not shown). When analyses on duration of
paracetamol use were carried out using spline regression to accommodate possible non-linear
relationships, the lack of association between duration of paracetamol use and wheezing was
confirmed.
Table 3 shows the results on paracetamol use for selected non-infectious disorders (sciatica,
headache, and migraine), separately in the first and in third trimester of pregnancy. Although
this analysis is based on relatively small numbers, we did not find evidence of an increased risk
of wheezing or asthma in the first 18 months of life among infants whose mothers took para-
cetamol to treat these non-infectious disorders compared to mothers that did not.
S4 Table reports the results of the associations (expressed as odds ratios) between maternal
conditions and paracetamol use by trimester, calculated for the propensity score-based analysis.
The propensity score itself was associated with the risk of ever and recurrent wheezing, with RRs
of 1.18 [95% CI 0.82–1.69] and 1.21 [95% CI 0.56–2.59] in the first trimester and RRs of 3.37
[95% CI 2.04–5.54] and 4.18 [95% CI 1.35–12.95] in the third trimester for each 1-unit increase.
When the propensity score was included in the regression models on paracetamol use and risk
of wheezing in infants, we obtained results similar to those in the main analysis reported in
Table 2 (first trimester: RRadjusted = 1.11 [95% CI 0.89–1.37] for ever wheezing and RRadjusted =
1.10 [95% CI 0.72–1.67] for recurrent wheezing/asthma; third trimester: RRadjusted = 1.05
Paracetamol Use in Pregnancy and Infant Wheezing
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Table 1. Maternal socio-demographic characteristics and potential confounders by paracetamol use during the first and third trimesters of preg-
nancy. NINFEA cohort study, 2005–2013.
Maternal characteristics and potential confounders Paracetamol use
First trimester Third trimester
Non-users Users Non-users Users
N = 2332 (%) N = 1026 (%) N = 2057 (%) N = 1194 (%)
Missing values: - Missing values: 107
Educational level
- University degree or higher 1423 (61.2) 582 (56.9) 1272 (62.0) 677 (57.0)
- Secondary school 789 (33.9) 389 (38.1) 688 (33.5) 446 (37.6)
- Primary school or less 112 (4.8) 51 (5.0) 92 (4.5) 64 (5.4)
- Missing values 8 4 5 7
Age at delivery (years)
- <30 443 (19.0) 230 (22.4) 403 (19.6) 246 (20.6)
- 30–34 1028 (44.1) 437 (42.6) 916 (44.5) 506 (42.4)
- 35–39 712 (30.5) 301 (29.3) 605 (29.4) 371 (31.1)
- 40 149 (6.4) 58 (5.6) 133 (6.5) 71 (5.9)
- Missing values 0 0 0 0
Smoking during pregnancy
- No 2148 (92.5) 936 (91.8) 1905 (93.0) 1086 (91.5)
- Yes 173 (7.4) 84 (8.2) 143 (7.0) 101 (8.5)
- Missing values 11 6 9 7
Siblings
- No 1827 (79.2) 730 (72.3) 1651 (81.3) 824 (69.8)
- Yes 480 (20.8) 280 (27.7) 380 (18.7) 357 (30.2)
- Missing values 25 16 26 13
Gestational duration (weeks)
- <37 81 (3.5) 42 (4.1) 74 (3.6) 45 (3.8)
- 37–42 2089 (89.6) 916 (89.3) 1836 (89.3) 1075 (90.0)
- 42 162 (6.9) 68 (6.6) 147 (7.1) 74 (6.2)
- Missing values 0 0 0 0
Asthma/asthmatic bronchitis
- Never 2169 (93.0) 927 (90.3) 1915 (93.1) 1083 (90.7)
- Ever 163 (7.0) 99 (9.7) 142 (6.9) 111 (9.3)
- Missing values 0 0 0 0
Allergic rhinitis/hay fever
- Never 2046 (87.7) 862 (84.0) 1808 (87.9) 1005 (84.2)
- Ever 286 (12.3) 164 (16.0) 249 (12.1) 189 (15.8)
- Missing values 0 0 0 0
Disorders during pregnancy
Otitis/sinusitis/throat infection
- No 2192 (94.5) 865 (84.3) 1992 (96.8) 1057 (88.5)
- Yes 128 (5.5) 161 (15.7) 65 (3.2) 137 (11.5)
- Missing values 12 0 0 0
Bronchitis or flu
- No 2284 (98.4) 971 (94.6) 2017 (98.1) 1075 (90.0)
- Yes 36 (1.5) 55 (5.4) 40 (1.9) 119 (10.0)
- Missing values 12 0 0 0
Cold
(Continued)
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[95% CI 0.85–1.30] for ever wheezing and RRadjusted = 0.89 [95% CI 0.58–1.337] recurrent
wheezing/asthma; data not shown in tables).
Discussion
We found a crude positive association between prenatal exposure to paracetamol and ever
wheezing and recurrent wheezing/asthma in infants. However, adjustment for confounders
that have been identified in studies on childhood wheezing and for maternal infections and fac-
tors associated with maternal infections during pregnancy substantially decreased the relative
risk estimates, even when a propensity score-based analysis was applied. Moreover, there was
no evidence of an association between duration of paracetamol use and the risk of wheezing in
children. Finally, we did not find an increased risk for maternal paracetamol use to treat non-
infectious disorders (sciatica and headache/migraine) and wheezing in infants. These results
suggest that confounding is a likely explanation for at least most of the association between
paracetamol use in pregnancy and wheezing in children.
Several cohort studies reported a positive association between prenatal exposure to paracet-
amol and wheezing or asthma in children (summarised in S5 and S6 Tables), but the lack of
complete adjustment for factors that could both indicate paracetamol use in pregnancy and
that are related to wheezing/asthma in children, was typically mentioned as a possible explana-
tion for the positive findings [3, 5, 8, 9, 22–24]. Several factors can be proxies of paracetamol
use during pregnancy, and at the same time may be related to wheezing or asthma in children
Table 1. (Continued)
Maternal characteristics and potential confounders Paracetamol use
First trimester Third trimester
Non-users Users Non-users Users
N = 2332 (%) N = 1026 (%) N = 2057 (%) N = 1194 (%)
Missing values: - Missing values: 107
- No 2013 (86.8) 715 (69.7) 1887 (91.7) 937 (78.5)
- Yes 307 (13.2) 311 (30.3) 170 (8.3) 257 (21.5)
- Missing values 12 0 0 0
Fever >38°C
- No 2280 (98.3) 956 (93.2) 2048 (93.9) 1097 (91.9)
- Yes 40 (1.7) 70 (6.8) 125 (6.1) 97 (8.1)
- Missing values 12 0 0 0
Sciatica
- No 1877 (80.5) 723 (70.5) 883 (42.9) 357 (29.9)
- Yes 455 (19.5) 303 (29.5) 1174 (57.1) 837 (70.1)
- Missing values 0 0 0 0
Headache/migraine
- No 2252 (96.6) 868 (84.8) 1965 (95.5) 957 (80.1)
- Yes 80 (3.4) 156 (15.2) 92 (4.5) 237 (19.8)
- Missing values 0 2 0 0
Antibiotic use during pregnancy
- No 2100 (90.3) 873 (85.1) 1852 (90.0) 1027 (86.0)
- Yes 226 (9.7) 153 (14.9) 205 (10.0) 167 (14.0)
- Missing values 6 0 0 0
doi:10.1371/journal.pone.0135775.t001
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(e.g. maternal asthma and allergic rhinitis). In addition, environmental factors that favour
maternal infections (e.g. maternal smoking, low socio-economic status, or parity) may affect
maternal paracetamol use and increase the risk of infections in infancy, which in turn may trig-
ger wheezing. In our study, we observed a large reduction in the estimates of the association
between maternal paracetamol use and wheezing in infancy when we adjusted for these envi-
ronmental factors and maternal asthma and allergies. Furthermore, we also had direct informa-
tion on maternal respiratory infections and associated variables (use of antibiotics, cold), and
adjustment for these factors further reduced our estimates towards unity.
Most of the previous studies adjusted for several potential confounders (listed in S5 and S6
Tables), and in general these adjustments consistently attenuated the positive estimates. How-
ever, a sizable and heterogeneous number of variables were usually adjusted for, making it diffi-
cult to understand the relative contribution of each confounder. Furthermore, among the
studies that examined the association between maternal paracetamol use and wheezing/asthma
in children (S5 and S6 Tables), very few were able to take into account maternal infections, par-
ticularly maternal respiratory infections. Shaheen et al. adjusted for some maternal infections
(cold/flu, urinary infections, other infections) and antibiotic use [22, 25], but only those that
occurred in late pregnancy; four studies considered only antibiotic use in pregnancy [9, 26, 27],
or in late pregnancy [23]. Our study shows that maternal infections during pregnancy contrib-
ute to confounding bias, and suggests that the lack of adequate control for this group of con-
founders could at least partly explain the large between-study heterogeneity that has been
previously observed [3].
In an attempt to analyse the effect of maternal paracetamol use while avoiding the problem
of confounding due to maternal infections, we used a novel approach: we analysed maternal
Table 2. Association between infant wheezing at 18 months and recurrent wheezing/asthma andmaternal paracetamol use in the first or third tri-
mester. NINFEA cohort study, 2005–2013.
Outcomes Paracetamol use
Number of cases Exposed cases RRcrude RRadjusted
§ RRadjusted
§§
N (%) [95% CI] [95% CI] [95% CI]
Ever wheezing First trimester
553 196 1.25 1.16 1.10
(35.4) [1.07–1.47] [1.00–1.37] [0.94–1.30]
Third trimester**
534 225 1.26 1.13 1.10
(42.1) [1.08–1.47] [0.96–1.32] [0.93–1.29]
Recurrent wheezing/asthma First trimester
185 67 1.30 1.15 1.10
(36.2) [0.97–1.73] [0.86–1.53] [0.82–1.49]
Third trimester**
178 68 1.07 0.89 0.81
(38.2) [0.80–1.43] [0.66–1.20] [0.60–1.11]
§ Adjusted for: maternal educational level, maternal age at delivery, maternal smoking during pregnancy, siblings, maternal asthma/asthmatic bronchitis,
maternal allergic rhinitis.
§§ Adjusted analysis for the same variables as footnote §, as well as for maternal infections (or factors associated with maternal infections) in the first/third
trimester of pregnancy: otitis/sinusitis/throat infections, bronchitis or flu, cold, fever, and antibiotic use during pregnancy.
**Adjusted further for gestational duration.
RR: risk ratio, CI: confidence interval.
doi:10.1371/journal.pone.0135775.t002
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paracetamol use for non-infectious disorders, including migraine, headache, and sciatica.
Results were still consistent, indicating no increased risk of wheezing in children for maternal
paracetamol use during pregnancy.
After adjustment, we did not find an association between wheezing and maternal paraceta-
mol use during either the first or third trimester of pregnancy. Had the effect been causal, the
timing of exposure to paracetamol use during pregnancy could have been related to biological
mechanisms [27, 28]. We did not ascertain paracetamol use in the second trimester of preg-
nancy, and thus we could not assess the effect of exposure throughout the entire pregnancy.
Available studies on timing of paracetamol exposure during pregnancy have reported con-
flicting results (S5 and S6 Tables): some studies found an increased risk for exposure to para-
cetamol only in late pregnancy [23, 25]; others for exposure in both early and late pregnancy
[12, 24, 27]; and still others, like our study, found no association in either early or late preg-
nancy [11].
As in other studies [13, 23, 25, 26], we focused our analysis on wheezing, or asthma diag-
nosed by a physician occurring in the first 18 months of life rather than on asthma at older
ages, given the relatively young age of our cohort. The use of asthmatic symptoms reported by
Table 3. Risk ratios (RR), and corresponding 95% confidence Intervals (CI), of ever wheezing and recurrent wheezing/asthma for maternal paracet-
amol use to treat sciatica or migraine or headache in the first and third trimester of pregnancy. NINFEA cohort study, 2005–2013.
Paracetamol use in the first trimester
Exposed cases RRcrude RRadjusted
§
(%) [95% CI] [95% CI]
Ever wheezing
Women affected by sciatica, migraine or headache and NOT using paracetamol to treat them 77 1.00 1.00
(82.8) ref ref
Women affected by sciatica, migraine or headache and using paracetamol to treat them 16 1.04 1.06
(17.2) [0.64–1.70] [0.65–1.72]
Recurrent wheezing/asthma
Women affected by sciatica, migraine or headache and NOT using paracetamol to treat them 28 1.00 1.00
(84.8) ref ref
Women affected by sciatica, migraine or headache and using paracetamol to treat them 5 0.90 0.91
(15.2) [0.36–2.26] [0.38–2.20]
Paracetamol use in the third trimester*
Exposed cases RRcrude RRadjusted
§
(%) [95% CI] [95% CI]
Ever wheezing
Women affected by sciatica, migraine or headache and NOT using paracetamol to treat them 106 1.00 1.00
(74.6) ref ref
Women affected by sciatica, migraine or headache and using paracetamol to treat them 36 0.76 0.70
(25.4) [0.54–1.07] [0.50–0.97]
Recurrent wheezing/asthma
Women affected by sciatica, migraine or headache and NOT using paracetamol to treat them 39 1.00 1.00
(84.8) ref ref
Women affected by sciatica, migraine or headache and using paracetamol to treat them 7 0.40 0.34
(15.2) [0.18–0.88] [0.15–0.74]
§ Adjusted analysis for: maternal educational level, maternal age at delivery, smoking in pregnancy, siblings, maternal asthma or asthmatic bronchitis,
maternal allergic rhinitis.
* Further adjusted for gestational duration.
doi:10.1371/journal.pone.0135775.t003
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the mother may involve a certain degree of misclassification; however, such misclassification
should not have been influenced by prenatal exposure to paracetamol, which is very commonly
used and is not directly linked with a fear of harmful effects on the respiratory health of chil-
dren. Since parents might wrongly label a single, isolated episode of noisy breathing as wheez-
ing [29], and since wheezing in infants can be a transient disorder, we also considered infants
with recurrent wheezing (i.e. at least two episodes of wheezing by the age of 18 months), a
more specific condition that reflects “actual” wheezing episodes or a more severe form of
wheezing, and also we obtained comparable results.
In our study, information on maternal paracetamol use and disorders during the first tri-
mester of pregnancy was collected at any time during the pregnancy, while information on the
third trimester was collected in the first follow-up questionnaire when the child turned 6
months old. As maternal paracetamol use was self-reported, it could be affected by some degree
of misclassification. However, this is expected to be non-differential, especially for the first tri-
mester, and likely biased the estimates towards the null. On the other hand, it could be under-
estimated due to exposure misclassification. It is reassuring that when we studied paracetamol
use to treat sciatica and headache/migraine, this exposure was not associated with the risk of
wheezing in children. The level of exposure misclassification in this analysis is likely to be
lower.
Our study was based on a relatively large cohort with baseline information on several recog-
nised risk factors for wheezing and asthma, including maternal educational level, smoking, and
various maternal infectious diseases and disorders during pregnancy. We specifically focused
on the role of confounding, adjusting for a large number of potential confounders and con-
ducting further analyses, including a propensity score-based analysis, to validate our results.
However, other factors not considered in the present analysis, e.g. maternal stress/anxiety [8],
could play a role in the association between maternal paracetamol use in pregnancy and child-
hood asthma, and deserve future investigation.
In conclusion, our results support the hypothesis that the repeatedly reported association
between maternal paracetamol use during pregnancy and infant wheezing can be mainly, if not
completely explained by confounding.
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